NorstellaLinQ dataset achieves highest scores on data quality for claims backbone real-world data (RWD) use cases and is now available to Atropos Evidence Network members
Atropos Health, the pioneer in translating real-world clinical data into high-quality personalized real-world evidence (RWE) for care, announces the availability of an initial dataset from NorstellaLinQ on the Atropos Evidence Network. Norstella LinQ, built by Norstella, one of the largest global pharma intelligence solution providers, is the first and only fully integrated data asset combining real-world data (RWD) and proprietary intelligence from the most trusted brands in the industry, paving the way for breakthroughs in drug development and commercialization. The addition of this initial dataset from NorstellaLinQ to the Atropos Evidence Network marks the next step in the strategic partnership between Atropos Health and Norstella, expanding upon the collaboration that is redefining speed to insight for the life sciences industry.
Atropos Evidence Network members can now benefit from this additional dataset when they use ChatRWD® and the Green Button™ to ask clinical questions. The Atropos Evidence Network, already the largest federated data network in healthcare with over 300M patient records, continues to be the data source of choice for life sciences leaders when making decisions along every phase of the drug development process - from R&D to commercialization. Life sciences leaders such as Merck, who recently announced the selection of Atropos Health as a premium platform, are generating RWE to accelerate the development of life-saving treatments. Other use cases for life sciences leaders include clinical trial recruitment, physician targeting and market sizing. Health system leaders and clinicians rely on RWE generated from the high quality RWD in the Atropos Evidence Network to inform shared decision-making at the point of care and when designing care protocols.
NorstellaLinQ is the biopharma industry’s first fully integrated data asset combining both RWD – including open and closed claims, lab results and structured and unstructured electronic medical records (EMR) — with Norstella’s proprietary forecasting, clinical, regulatory, payer, coverage and commercial intelligence data. NorstellaLinQ integrates more than 74 billion data points — including the insights of 500,000 investigators, tens of thousands of clinical trials across 185 countries, hundreds of brand launches, and tens of thousands of forecasts. Today, Norstella is making available an initial dataset from Norstella LinQ on the Atropos Evidence Network including open medical and pharmacy claims. When evaluated by Atropos Health’s independent Real World Data Score ® (RWDS) methodology, this dataset scores in the top percentile, being rich in diagnosis and procedure data and including wide coverage of diagnosis data across major diagnostic groupings. The dataset is fit to answer challenging questions across commercialization, HEOR, and R&D use cases, as evidenced by the high Real World Fitness Score® (RWFS). The quality and breadth of this initial dataset from NorstellaLinQ allowed for many existing studies to be re-run on a wide variety of therapeutic areas, outperforming industry benchmarks in both specific therapeutic areas and as a holistic view of patients. Norstella and Atropos Health are already working to expand with more data from NorstellaLinQ on the Atropos Evidence Network, made possible by Norstella’s agile platform and application of innovative tools, like Generative AI and machine learning, to provide even higher quality, comprehensive patient information.
"Continuing to add high quality datasets to the Atropos Evidence Network elevates the healthcare industry’s ability to ensure the advancement of evidence-based medicine," said Dr. Brigham Hyde, CEO and Co-Founder, Atropos Health. "The team at Norstella has raised the bar on quality and breadth for claims-based RWD, and we are pleased to continue our partnership and bring this first dataset from NorstellaLinQ to Atropos Health users and Atropos Evidence Network members."
Norstella is now benefiting from the Data Quality Scorecard from Atropos Health, offered to all data holder members of the Atropos Evidence Network. The Real World Data Score® (RWDS) and RWFS provided Norstella with objective scoring and suggestions for improving as well as an understanding of how their score compared to other network members. The methodology for calculating these scores can be found in MedRxiv.
"We are incredibly pleased to see the high scores on the Data Quality Scorecard for this NorstellaLinQ dataset produced by Atropos Health’s Independent and transparent scoring process," said Mike Gallup, CEO of Norstella." NorstellaLinQ presents an exciting alternative to Life Science companies facing concerns over reliable data sourcing for any number of key use cases across Commercial and R&D."
This announcement comes on the heels of Atropos Health’s recent announcement of partnerships with Arcadia, Xcures, and Scipher, further broadening the diversity and quality of data available on the Atropos Evidence Network.
About Atropos Health
Atropos Health is the developer of GENEVA OS™, the operating system for rapid healthcare evidence across a robust network of real-world data. Healthcare and life science organizations work with Atropos Health to close evidence gaps from bench to bedside, improving individual patient outcomes with data-driven care, expediting research that advances the field of medicine, and more. We aim to transform healthcare with timely, relevant real-world evidence.
To learn more about Atropos Health, visit www.atroposhealth.com or connect through LinkedIn or follow on X (Twitter) @AtroposHealth.
About Norstella
At Norstella, our mission is simple: to smooth the path to life-saving therapies for patients and providers. As one of the largest global pharma intelligence solution providers, Norstella unites market-leading companies—Citeline, Evaluate, MMIT, Panalgo, and The Dedham Group—that offer a full range of clinical and commercial solutions and consultancy services. As one organization, Norstella provides life sciences clients with the right tools and expertise to navigate complexities at each step of the drug development life cycle, from pipeline to patient. For more information, visit Norstella and follow us on LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250204889025/en/
Contacts
Media contacts
Atropos@solcomms.co
